A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy

被引：144
作者：
Awuah, Samuel G. [1 ]
Zheng, Yao-Rong [1 ]
Bruno, Peter M. [2 ]
Hemann, Michael T. [2 ]
Lippard, Stephen J. [1 ,2 ]
机构：
[1] MIT, Dept Chem, Cambridge, MA 02139 USA
[2] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA
来源：
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY | 2015年 / 137卷 / 47期
关键词：
INDOLEAMINE 2,3-DIOXYGENASE EXPRESSION; DENDRITIC CELLS; TRYPTOPHAN CATABOLISM; IDO EXPRESSION; T-CELLS; INHIBITION; MECHANISMS; CISPLATIN; THERAPY; STRATEGIES;
D O I：
10.1021/jacs.5b10182
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Expression of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive enzyme in human tumors, leads to immune evasion and tumor tolerance. IDO is therefore a tumor immunotherapeutic target, and several IDO inhibitors are currently undergoing clinical trials. ID inhibitors can enhance the efficacy of common cancer chemotherapeutics. Here we investigate Pt(IV)-(D)-1-methyltryptophan conjugates 1 and 2 for combined immunomodulation and DNA cross-link-triggered apoptosis for cancer "immuno-chemotherapy". Compound 2 effectively kills hormone-dependent, cisplatin-resistant human ovarian cancer cells, inhibiting IDO by transcriptional deregulation of the autocrine-signaling loop IDOAHR-IL6, which blocks kynurenine production and promotes T-cell proliferation. Additionally, 1 and 2 display low toxicity in mice and are stable in blood. To our knowledge, this construct is the first Pt drug candidate with immune checkpoint blockade properties.
引用
收藏
页码：14854 / 14857
页数：4
相关论文
共 34 条
  • [1] [Anonymous], 2014, CANC IMM
  • [2] Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer:: Effect on tumor-infiltrating T cells
    Brandacher, G
    Perathoner, A
    Ladurner, R
    Schneeberger, S
    Obrist, P
    Winkler, C
    Werner, ER
    Werner-Felmayer, G
    Weiss, HG
    Göbel, G
    Margreiter, R
    Königsrainer, A
    Fuchs, D
    Amberger, A
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (04) : 1144 - 1151
  • [3] Rapid biotransformation of satraplatin by human red blood cells in vitro
    Carr, JL
    Tingle, MD
    McKeage, MJ
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (01) : 9 - 15
  • [4] Cancer Immunotherapy
    Couzin-Frankel, Jennifer
    [J]. SCIENCE, 2013, 342 (6165) : 1432 - 1433
  • [5] Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate
    Dhar, Shanta
    Lippard, Stephen J.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (52) : 22199 - 22204
  • [6] Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients
    Erdlenbruch, B
    Nier, M
    Kern, W
    Hiddemann, W
    Pekrun, A
    Lakomek, M
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (05) : 393 - 402
  • [7] Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches
    Galanski, M
    Jakupec, MA
    Keppler, BK
    [J]. CURRENT MEDICINAL CHEMISTRY, 2005, 12 (18) : 2075 - 2094
  • [8] Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
    Godin-Ethier, Jessica
    Hanafi, Laila-Aicha
    Piccirillo, Ciriaco A.
    Lapointe, Rejean
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (22) : 6985 - 6991
  • [9] Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses
    Hou, De-Yan
    Muller, Alexander J.
    Sharma, Madhav D.
    DuHadaway, James
    Banerjee, Tinku
    Johnson, Maribeth
    Mellor, Andrew L.
    Prendergasts, George C.
    Munn, David H.
    [J]. CANCER RESEARCH, 2007, 67 (02) : 792 - 801
  • [10] Jiang H, 2011, NAT CHEM BIOL, V7, P92, DOI [10.1038/nchembio.503, 10.1038/NCHEMBIO.503]
1234